Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 September 2020 | Story Leonie Bolleurs | Photo Supplied
With the research grant awarded to Dr Thulisile Mphambukeli, she has the opportunity to make a difference in society, especially in terms of the incorporation of social justice into planning.

The Joint National Institute for the Humanities and Social Sciences (NIHSS) and Chinese Academy of Social Sciences (CASS) research projects have awarded a R500 000 research grant to a team led by Dr Thulisile Mphambukeli, the principal investigator (PI). 

Within the parameters of the theme of social justice, sustainable development, and quality of life, Dr Mphambukeli’s team will focus their research on exploring the land policies in BRICS that inform agricultural practices. They will also document the policy approaches and strategies adopted by China and South Africa respectively to support the agriculture-land-water-labour nexus; additionally, they will propose a common agricultural land policy for China and South Africa. 

The title of the research project is: Exploring the Situated Political Ecology and Economy of Agricultural Land Policies in BRICS: A Case Study of China and South Africa. 

Dr Mphambukeli, who is passionate about social justice, is a Senior Lecturer in the Department of Urban and Regional Planning at the University of the Free State (UFS). With this project, she has the opportunity to make a difference in society, especially in terms of social justice. 

 

We don’t want to see the next generation suffer because we did not use our voice.- Dr Thulisile Mphambukeli

The human factor is crucial

“We need to understand the dynamics of local communities. The incorporation of social justice in planning is crucial! We cannot claim that we ‘plan for people’ and ignore them at the same time. People must be at the centre of what we do. No one must be deprived of their fundamental basic human rights.”

The team consists of Dr Mphambukeli (PI), Prof Peliwe Lolwana (University of the Witwatersrand), Dr Victor Okorie (Enugu State University of Science and Technology, Nigeria), and Dr Abraham Matamanda (UFS).

For this initiative, the China Africa Institute (CAI), which is part of CASS, joined hands with the NIHSS. Together, they will oversee the research projects of researchers and academics from South Africa and China. The research project, running from 1 April this year to 31 March 2021, will bring forth publications/research outputs, advocacy policy briefs, and proceeding reports.

The programme aims to strengthen research in the field of the humanities and social sciences between the two countries. 

Support the fight against climate change

She believes that although the BRICS countries are not geographically connected, it is a functional community with the same interests. “As BRICS countries, we need to cooperate in the fight against climate change. It affects so many components, including water, food, agriculture, land, and quality of infrastructure,” says Dr Mphambukeli. 

Due to the current COVID-19 pandemic, researchers will meet online to discuss how China and South Africa can collaborate and cooperate. “We don’t want to see the next generation suffer because we did not use our voice,” she says. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept